Could natural killer cells transform Alzheimer’s treatment?

Beyond Biotech - the podcast from Labiotech

A US company, with its origins in South Korea, is using natural killer (NK) cells to treat Alzheimer’s disease, with remarkable results.

This week, we have a conversation with Dr Paul Song, CEO of NKGen Biotech, a company with its sights set on changing the Alzheimer’s treatment landscape.

00:58-02:55: About NKGen Biotech
02:56-05:39: Why is Alzheimer’s so challenging to treat?
05:39-07:28: Are there other treatments making a difference?
07:28-13:47: What is NKGen Biotech’s approach to treating Alzheimer’s?
13:47-15:38: Can you treat multiple conditions at the same time?
15:38-15:55: Are there any side effects?
15:55-16:33: What dose are you able to give?
16:33-18:31: How can you keep the cost of treatments low?
18:31-19:19: How, and how often, will it be administered?
19:19-20:49: How are you approaching taking on later stage Alzheimer’s?
20:49-22:21: Are you looking to cure Alzheimer’s?
22:21-23:50: Can this approach be used for other diseases?
23:50-24:47: Are you looking for partnerships?
24:47-25:47: What stage are your trials at?
25:47-26-19: What are the next steps for NKGen Biotech?
26:19-26:35: How are you enrolling patients?
26:35-27:32: What is your approximate timeline?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Kapitel

1. Could natural killer cells transform Alzheimer’s treatment? (00:00:00)

2. About NKGen Biotech (00:00:58)

3. Why is Alzheimer’s so challenging to treat?
 (00:02:56)

4. Are there other treatments making a difference?
 (00:05:39)

5. What is NKGen Biotech’s approach to treating Alzheimer’s?
 (00:07:28)

6. Can you treat multiple conditions at the same time? (00:13:47)

7. Are there any side effects?
 (00:15:38)

8. What dose are you able to give? (00:15:55)

9. How can you keep the cost of treatments low?
 (00:16:33)

10. How, and how often, will it be administered?
 (00:18:31)

11. How are you approaching taking on later stage Alzheimer’s? (00:19:19)

12. Are you looking to cure Alzheimer’s?
 (00:20:49)

13. Can this approach be used for other diseases?
 (00:22:21)

14. Are you looking for partnerships? (00:23:50)

15. What stage are your trials at? (00:24:47)

16. What are the next steps for NKGen Biotech?
 (00:25:47)

17. How are you enrolling patients?
 (00:26:19)

18. What is your approximate timeline? (00:26:35)